Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease

Abstract

The present invention relates to a composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease, more precisely a composition containing separated or proliferated cells from umbilical cord blood for intratracheal administration for treating developmental and/or chronic lung disease. The cells of the composition of the present invention have excellent activities of proliferation and differentiation, so that the extraction, separation and selection of a tissue donor are all very easy. Besides, the composition of the invention can be very effectively used for the treatment of developmental and/or chronic diseases by intratracheal administration.

1 . A composition for treating developmental and/or chronic lung disease comprising cells separated or proliferated from umbilical cord blood. 
   
   
       2 . The composition for treating developmental and/or chronic lung disease according to  claim 1 , wherein the cells are one or more cells selected from a group consisting of monocytes, such as autologous hematopoietic stem cells, and mesenchymal stem cells separated from umbilical cord blood and mesenchymal stem cells sub-cultured and amplified from umbilical cord blood derived mesenchymal stem cells. 
   
   
       3 . The composition for treating developmental and/or chronic lung disease according to  claim 1 , which additionally includes a medium for those separated and proliferated cells. 
   
   
       4 . The composition for treating developmental and/or chronic lung disease according to  claim 3 , wherein the medium is selected from a group consisting of DMEM, MEM, alpha-MEM, McCOys 5A medium (Gibco), Eagle's basal medium, CMRL medium, Glasgow minimum essential medium, Ham's F-12 medium, Iscove's modified Dulbecco's medium, Liebovitz' L-15 medium and RPMI 1640 medium. 
   
   
       5 . The composition for treating developmental and/or chronic lung disease according to  claim 1 , wherein the composition is intratracheally administered into a patient. 
   
   
       6 . The composition for treating developmental and/or chronic lung disease according to  claim 1 , wherein the chronic lung disease is selected from a group consisting of cystic fibrosis, chronic obstructive pulmonary disease or pulmonary dysplasia. 
   
   
       7 . The composition for treating development and/or chronic lung disease according to  claim 1 , wherein the composition includes one or more subsidiary components selected from a group consisting of serum, antibiotics and antifungal agents. 
   
   
       8 . The composition for treating developmental and/or chronic lung disease according to  claim 1 , wherein the composition includes one or more subsidiary components selected from a group consisting of fetal bovine serum, horse serum, human serum, Penicillin G, streptomycin sulfate, amphotericin B, gentamycin and nystatin.